Education
About Us
Working with TipRanks
Follow Us
Curative Biotechnology Inc (CUBT)
:CUBT
CUBT Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume185.23K
Average Volume (3M)48.73K
Market Cap
$9.94M
Enterprise ValueN/A
Total Cash (Recent Filing)$304.35K
Total Debt (Recent Filing)$2.47M
Price to Earnings (P/E)―
Beta-0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding903,263,370
10 Day Avg. Volume65,591
30 Day Avg. Volume48,726
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-2.76
Price to Sales (P/S)0.00
P/FCF Ratio-25.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CUBT FAQ
What was Curative Biotechnology Inc’s price range in the past 12 months?
Curative Biotechnology Inc lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Curative Biotechnology Inc’s market cap?
Curative Biotechnology Inc’s market cap is $9.94M.
When is Curative Biotechnology Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Curative Biotechnology Inc’s earnings last quarter?
Curative Biotechnology Inc released its earnings results on May 25, 2021. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is Curative Biotechnology Inc overvalued?
According to Wall Street analysts Curative Biotechnology Inc’s price is currently Overvalued.
Does Curative Biotechnology Inc pay dividends?
Curative Biotechnology Inc does not currently pay dividends.
What is Curative Biotechnology Inc’s EPS estimate?
Curative Biotechnology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curative Biotechnology Inc have?
Curative Biotechnology Inc has 903,263,370 shares outstanding.
What happened to Curative Biotechnology Inc’s price movement after its last earnings report?
Curative Biotechnology Inc reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Curative Biotechnology Inc?
Currently, no hedge funds are holding shares in CUBT
Company Description
Curative Biotechnology Inc
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
Technical Analysis
Biomerica
―
Predictive Oncology
―
Immuron
―
Co-Diagnostics
―
Intelligent Bio Solutions
―